Changing the Practice of Medicine. The Novartis Institutes for BioMedical Research
|
|
- Lawrence Griffin
- 6 years ago
- Views:
Transcription
1 Changing the Practice of Medicine The Novartis Institutes for BioMedical Research
2 2 Changing the Practice of Medicine
3 Welcome to the Novartis Institutes for BioMedical Research The Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis committed to discovering innovative medicines to treat diseases with high unmet medical need. There is no greater privilege than to work toward bettering human health, and no more exciting arena in which to do so than through discovery of new medicines. Mark Fishman President, NIBR With more than 6,000 scientists, physicians and business professionals around the world, we have an open, entrepreneurial and innovative culture that encourages collaboration as we work to push the boundaries of science to change the practice of medicine. Emeryville, CA, USA La Jolla, CA, USA Cambridge, MA, USA East Hanover, NJ, USA Basel, Switzerland Shanghai, China Singapore 3 Changing the Practice of Medicine
4 Focus on the Patient, Follow the Science My disease affects so few people; no one cared to research a treatment until now. Siobhan Walsh, Rare disease patient At the earliest stages of research, our drug discovery priorities are determined by patient need and sound science not the potential market size of a medicine. Rare Diseases Rare disease research is central to our approach. We focus on rare diseases for two reasons, because they affect patients who are in critical need of new medicines and they often have a uniform underlying genetic cause. This allows us to determine quickly whether our medicine will work in patients. Once we know that a medicine is working, we can expand to broader more complex diseases. Currently we have research projects in more than 40 rare diseases across a broad disease spectrum. Diseases of the Developing World NIBR also focuses on diseases of the developing world. Our efforts include tropical infectious diseases, such as malaria, TB, and infectious diarrhea, three of the four top killer diseases in the world s tropical regions. It also includes other wide-spread infectious diseases, such as Dengue Fever, common across the tropical regions, and Chagas Disease, common in Latin America. Our vaccine efforts are centered on typhoid fever that mostly affects children across Africa, Southeast Asia and Latin America. In addition, our portfolio encompasses cancers that disproportionately affect people in the developing world. One example is liver cancer, caused by Hepatitis infections common in Southeast Asia and parts of Africa. 4 Changing the Practice of Medicine
5 Our Approach Pathways to New Medicines One of the great challenges in drug discovery is finding new drug targets (proteins associated with disease) that can be treated by medicines. NIBR meets this challenge by mapping the complex network of signaling pathways in cells. Signaling pathways are the communication highways inside a cell. Like circuitry in a machine, pathways carry important impulses that control all cell functions. Simply put, a breakdown or imbalance at any point along a pathway is the root cause of disease. NIBR investigates how compounds alter pathway function and then connects this information to associated diseases. 1. The interconnected proteins in molecular signaling pathways are responsible for normal cell function. Proof-of-Concept Clinical Trials Scientists and physicians at NIBR have broken down the boundaries between research and clinical practice to collaborate at the earliest stages of the Research & Development process. We believe we can better answer the demand for safer, more effective medicines by keeping our sights on both the science and the patient. To do this we use Proof-of-Concept (PoC) clinical trials small-scale studies in well-defined patient groups to get an early read-out on a drug s safety and effectiveness, and advance the most promising drug candidates. Wherever possible, especially when mechanisms are shared, several diseases are explored in parallel PoC trials. 2. The proteins receive and send molecular signals along a pathway. The signals tell the cell how to function and guide it through its life cycle. Strategic Scientific Alliances Novartis is a global collaborator of choice for biotechnology companies and academic centers seeking to discover and develop drugs for a range of diseases. Through the NIBR Strategic Alliances Group, NIBR has established productive alliances with more than 300 collaborators worldwide. We continue to look for new ways to combine our own scientific knowledge and expertise with that of the broader research community, to find the shortest path to new treatments for disease. 3. When anything goes awry in a pathway, it can cause disease. 4. Novartis hopes to develop drugs that will restore normal pathways function and treat disease. 5 Changing the Practice of Medicine
6 Innovative Research Disease Areas Our commitment to understanding the underlying molecular basis of disease has enabled us to deepen our knowledge, and turn scientific insights into medical breakthroughs. Innovative Research Discovery, Pre-Clinical and Clinical Sciences We bring new technologies to bear on understanding the fundamental science behind both normal and diseaserelated human biology. Autoimmunity, Transplantation, & Inflammatory Disease Rheumatoid arthritis, Multiple sclerosis, transplantation, psoriasis, lupus Analytical Sciences Protein and DNA analysis technologies Cardiovascular & Metabolic Diseases Heart disease, heart failure, hypertension, Type 2 diabetes Biologics Antibody, protein or sirna-based drug development Oncology Many types of cancer Chemistry Designing and creating potential new drugs Infectious Diseases Hepatitis B & C, Staph. aureus infection Developmental and Molecular Pathways Understanding and modulating signal transduction networks involved in disease Musculoskeletal Diseases Osteoporosis, muscle atrophy, sarcopenia Neuroscience Neuropsychiatric and neurodegenerative diseases Friedrich Miescher Institute for Biomedical Research Discovery of basic molecular mechanisms of cells and organisms in health and disease Genomics Institute of the Novartis Research Foundation Contributes new therapeutic targets, technologies and drug discovery Ophthalmology Glaucoma, Macular degeneration Imaging Molecular, cellular and clinical imaging Respiratory Diseases Idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, cystic fibrosis Metabolism and Pharmacokinetics Predicting how drug leads will behave in the body Proteomic Chemistry Studying the interaction of chemistry and biology 6 Changing the Practice of Medicine
7 Innovative Research Translational Sciences NIBR incorporates clinical medicine into its early stage benchtop drug discovery. Biomarker Development Accelerating drug development by identifying measurable biological factors (biomarkers) that are indicators of disease Developing World Diseases Novartis has large globally integrated programs in neglected diseases with a particular focus on parasitic diseases for which therapy is ineffective or toxic. NITD is dedicated exclusively to developing world disease research. Novartis Institute for Tropical Diseases Tuberculosis, Dengue, Malaria Drug Metabolism and Pharmacokinetics Optimizing the performance of a new drug Preclinical Safety Focusing on drug safety is Priority 1 Translational Medicine Translating biology into medicine Read about our latest research at Our drug discovery priorities are determined by patient need and sound science not the potential market size of a medicine. 7 Changing the Practice of Medicine
8 Innovative Culture Awards and Recognition We are proud to have been recognized by leading business and science publications. Selected recognition includes: Great Place to Work Top 25 World s Best Multinational Workplaces 2015 Fortune s World s Most Admired Companies 2014 Barron s World s Most Respected Companies 2014 the 2013 Scrip Award for Best Advance in an Emerging Market No. 1 ranking in DiversityInc s Top 50 Global Diversity Companies 2014 Thomson Reuters 2014 Top 100 Global Innovators 2014 Global Aon Hewitt Top Companies for Leaders Novartis Postdoctoral Program among The Scientist s Best Places to Work 2013 Innovative drug discovery does not happen in silos. It is driven by networks of scientists working together in teams across disciplines and geographies. Recognizing this, NIBR strives to have a diverse, inclusive and collaborative culture where scientists can tackle the complexity of drug discovery research together. Driven by the urgent needs of patients, and recognizing that no single individual can find cures, NIBR s team-based global drug discovery network embraces the diversity of knowledge, expertise, thinking styles, and identities of our more than 6,000 scientists, clinicians and business professionals. Individuals and teams are empowered to apply their skills and pursue their inspiration in the pursuit of the discovery of new medicines to help patients. At NIBR we are committed to hiring scientists, physicians and business professionals who seek to work in an atmosphere where patients come first and innovation is rewarded. 8 Changing the Practice of Medicine
9 Opportunities for Personal and Professional Growth One of the most valuable benefits of working at NIBR is the opportunity to continuously interact with colleagues across the globe who have very distinct skill sets and specific expertise areas. We provide a myriad of opportunities for individuals to grow professionally through organized training, coaching, and experiences. The Mini-Sabbatical program is an opportunity for ongoing teaching and learning interactions that enhance the sociology of innovation. Associates at NIBR have the opportunity to experience another country or change their job for a few months. The Developing World Sabbatical provides experienced NIBR scientists with mentoring or coaching opportunities with people from the developing world. The Developing World Sabbatical program aims at expanding NIBR scientist s horizon by experiencing new areas of research in a different cultural environment. This program provides the opportunity to increase understanding of medical needs in the developing world and local efforts to address them; and contributes to the scientific capability building in the developing world by helping the community through connections with local hospitals, research institutions, and universities. Our postdoctoral program provides talented scientists with a unique opportunity to perform high-quality research in an environment with the resources of a large pharmaceutical company. Each year, innovative researchers from academia are selected to become fellows and collaborate with leading pharmaceutical discovery scientists pursuing multidisciplinary research projects. Together, they apply their expertise to discovering new medicines that will help patients lead healthier lives. 9 Changing the Practice of Medicine
10 Innovation in Action A Case Study: Discovering the Next Generation of Malaria Drugs According to the World Health Organization (WHO), in 2008 there were approximately 247 million cases of malaria, causing nearly one million deaths, mostly among young children in Africa. Although malaria is preventable and curable, it is estimated that in Africa, a child dies every 45 seconds from the disease. 1 The Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria. NITD609 is a novel, synthetic antimalarial molecule belonging to the spiroindolone class. Awarded the Medicines for Malaria Venture s Project of the Year 2009, NITD609 is one of only a handful of molecules capable of curing P. berghei a preclinical mouse model of blood-stage malaria. NITD 609 is an investigational drug, which if proven safe, will be the first antimalarial not belonging to either the artemisinin or peroxide class to enter clinical efficacy studies. 1 A Case Study: Inhibiting the Hedgehog Pathway in Cancer A central principle of NIBR strategy is the critical importance of signaling pathways in human biology and disease. A relatively small number of core pathways play fundamental roles during embryonic development as well as later in life. Nature is deeply conservative and these core pathways are used time and again across species. Defects in major pathway components are the underlying cause of disease and provide targets for discovery of innovative therapies. Uncontrolled activation of the hedgehog pathway, discovered as part of a series of pioneering experiments in the 1970s, is known to be involved in cancers including basal cell carcinoma, the most common form of cancer. A key node or protein in the hedgehog pathway is a gene called Patched 1 that acts as a negative control, obstructing signal transduction except when activated by chemical messengers from outside the cell. An inherited mutation in Patched 1 causes a rare genetic disorder called Nevoid Basal Cell Carcinoma syndrome (Gorlin syndrome), in which patients repeatedly develop basal cell cancers. The cancers can be removed surgically but lead to the accumulation of disfiguring scars. Somatic mutations which occur during life, by contrast to inherited mutations can lead to sporadic basal cell cancer. NIBR scientists at the Genomics Institute of the Novartis Research Foundation in La Jolla, California, discovered an investigational compound known as LDE225 that can halt the abnormal signaling. LDE225 works by inhibiting a gene called Smoothened, located downstream from Patched 1 in the hedgehog pathway. LDE225 has been developed into a topical formulation that is applied to the skin at the site of basal cell cancers. A proof-of-concept study for LDE225 in treatment of patients with Gorlin syndrome was declared successful in Changing the Practice of Medicine
11 11 Changing the Practice of Medicine
12 Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue, Cambridge, MA 02139, USA Tel:
MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE
MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE THE RESEARCH WE DO TODAY WILL DETERMINE THE TYPE OF MEDICAL AND SURGICAL PRACTICE WE CARRY ON AT THE CLINIC
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationSSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview
SSPPS STRATEGIC PLAN Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice April 30, 2012 Overview Here we present the 2012-2017 strategic plan for the Skaggs School of Pharmacy
More information+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA
At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More information2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships
2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships Call Identifier: TMA2017IF The purpose of this Call for Proposals is to provide funding towards actions that aim to support
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationTestimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association
Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationOpportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
More informationThe Integrated Biomedical Sciences Graduate Program
The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to
More informationResearch Strategy Delivering internationally excellent research for a healthy, safe and sustainable society
Research Strategy 2016-2018 Delivering internationally excellent research for a healthy, safe and sustainable society Mission The College of Biomedical and Life Sciences aims to deliver internationally
More information7 Sexual Health.
RESE ARCH & DEVELOPMENT 22 Highlights Signed an agreement with Medicines for Malaria Venture (MMV) to provide MMV with access to the Pfizer library of novel chemical entities to screen for compounds that
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationBachelor of Science (Hons) / Bachelor of Science Biomedical Science
Bachelor of Science (Hons) / Bachelor of Science Biomedical Science Awarded by In collaboration with This degree course is designed to give you a broad understanding of the scientific investigation of
More informationUNDERSTANDING GENETIC RESEARCH AND ALTERNATING HEMIPLEGIA OF CHILDHOOD. IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process
IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process Genetic discovery AHC Patients Need Help! Researchers collect data on AHC patients (observation) Researchers interpret and evaluate data AHC
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationFOR ANIMALS FOR HEALTH FOR YOU
FOR ANIMALS FOR HEALTH FOR YOU WE HAVE A SINGULAR FOCUS ON ANIMAL HEALTH Zoetis is the world leader in animal health. We discover, develop, manufacture and market veterinary medicines and vaccines, complemented
More informationPost-doctoral PharmD Fellowship Programs
Post-doctoral PharmD Fellowship Programs Table of Contents About Bioverativ Messages from Medical & Regulatory Our Pipeline Partnership with Northeastern University Global Medical Fellowship Global Regulatory
More informationRoche in Switzerland
Roche in Switzerland A leader around the world and at home Last year Roche employed some 13,000 employees from over 90 countries in Switzerland. This makes Switzerland one of Roche s three largest locations
More informationMalaria Research Capability Strengthening in Africa
October 2004 UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR) Multilateral Initiative on Malaria (MIM) Malaria Research Capability Strengthening in Africa
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationINVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE!
INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! TOPADUR PHARMA AG a promising Swiss start-up investment Global Medical Need: Diabetes mellitus is one of the major health concerns worldwide.
More informationMalaria Research Capability Strengthening in Africa
July 2005 UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR) Multilateral Initiative on Malaria (MIM) Malaria Research Capability Strengthening in Africa INTRODUCTION
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationGREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014
GREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014 1982 WHAT HAS HAPPENED SINCE IN TECHNOLOGY ASSESSMENT AND. US Orphan Drug
More informationIs the grass greener on the other side.? Academia to Industry Stephen B. Helliwell
Is the grass greener on the other side.? Academia to Industry Stephen B. Helliwell Senior Investigator, Novartis Institutes for BioMedical Research Is the grass greener? http://eatrio.net/2013/04/portuguese-idioms-joao-sem-braco.html
More informationLecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry
Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Clinical proteomics is the application of proteomic approach to the field of medicine. Proteome of an organism changes
More informationPfizer Supports The Global Fight Against Malaria And Commemorates World Malaria Day Counting Malaria Out
For immediate release: April 24, 2009 Media Contact: Marco Winkler (212) 733 9313 Pfizer Supports The Global Fight Against Malaria And Commemorates World Malaria Day Counting Malaria Out NEW YORK, NY,
More informationThe Pathways to Understanding Diseases
FOR PHARMA & LIFE SCIENCES White paper The Pathways to Understanding Diseases Deciphering complex biological processes Executive Summary Understanding complex biological processes is critical whether doing
More informationVoyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat
More informationBSc BIOMEDICAL SCIENCE
Overview College of Science Biomedical Science Core March 2017 (1) BSc BIOMEDICAL SCIENCE Biomedical Science Degree 2015 1 College of Science, NUI Galway Fullscreen Next page Overview [60 credits] [60
More informationNovartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program
Novartis Business Services HR University Relations Clinical Sciences and Innovation Postgraduate Program 2 CLINICAL SCIENCES AND INNOVATION CLINICAL SCIENCES AND INNOVATION 3 The CS&I Postgraduate Program
More informationMessage from Genentech s Executive Sponsor
Message from Genentech s Executive Sponsor Dear Prospective Fellow: Genentech is excited to be a part of the University of the Pacific s Fellowship in Industry Program (FIP) for Doctor of Pharmacy graduates.
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationTRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS
TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS THE DOORS ARE OPEN: FEEL FREE TO COME IN CENTOGENE UNLOCKS THE POWER OF GENETIC INSIGHTS TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH GENETIC
More informationRare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationGUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS
GUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS 1. Introduction 1.1 This document provides guidance notes for the assessment of academic qualifications that have not been formally accredited
More informationOur people. Employee engagement and talent retention Compensation/benefits Leadership commitments Organisational effectivenesss
Our people Our employees are making a valuable difference for patients and are committed to doing their very best work with integrity, courage and passion. Material topics covered in this chapter Employee
More informationDrug Reposition & Open Innovation Initiatives: potential paths to new therapies and advancing medical science
Duke Law Center for Innovation Policy New Approaches and Incentives in Drug Development Washington D.C., November 22, 2013 Drug Reposition & Open Innovation Initiatives: potential paths to new therapies
More informationTogether, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days
Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants
More informationsirna Overview and Technical Tips
1 sirna Overview and Technical Tips 2 CONTENTS 3 4 5 7 8 10 11 13 14 18 19 20 21 Introduction Applications How Does It Work? Handy Tips Troubleshooting Conclusions Further References Contact Us 3 INTRODUCTION
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationStem cells and motor neurone disease
Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationBIOMEDICAL RESEARCH CENTRES
Introduction BIOMEDICAL RESEARCH CENTRES The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the
More informationHolland Innovation Network Team Boston: Walter de Wit Julia Knoeff
Holland Innovation Network Team Boston: Walter de Wit Julia Knoeff Boston and Cambridge in Massachusetts are innovation-focused hubs with world-leading universities such as Harvard, Boston University and
More informationDealdoc. Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon.
Dealdoc Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon Oct 18 2010 Marketing agreement for Recombinant Human Insulin, Glargine, Aspart
More informationPrescription for Innovation. Improving health and economic well-being in Northern Ireland
Prescription for Innovation Improving health and economic well-being in Northern Ireland INTRODUCTION The Association of the British Pharmaceutical Industry (ABPI) represents more than 80 pharmaceutical
More informationA BioPontis Alliance Report. Integrating Rare Disease Patients into Pre-Clinical Therapy Development; Finding our Way with Patient Input
A BioPontis Alliance Report Integrating Rare Disease Patients into Pre-Clinical Therapy Development; Finding our Way with Patient Input December 2016 Integrating Rare Disease Patients into Pre-Clinical
More informationBIOTECH IN FRANCE. key info in. points
BIOTECH IN FRANCE 10 key info in points 1 2 3 INSERM: EUROPE S #1 ACADEMIC BIOTECH RESEARCH INSTITUTE INSERM spearheads healthcare and medical research in France, filing more biotech patents with the European
More informationPHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14
PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14 Submitted resources from physician organization representatives were mapped
More informationGenomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)
Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome
More informationEnvigo Corporate & Industry Overview. Rutgers University
Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research
More informationClinical Trials in Taiwan Regulatory Achievement and Current Status
Clinical Trials in Taiwan Regulatory Achievement and Current Status Hui-Po Wang, Ph.D. Director General, Bureau of Pharmaceutical Affairs, Department of Health, Taiwan Sue, Shu-Yi Chen, Pharmacist Division
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationLA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES
LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES Francesca Pasinelli Direttore Generale 3 Congresso Nazionale SIFaCT Roma, 9 ottobre 2015 About Telethon Fondazione Telethon is
More informationBIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS
BIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS Supported By: Organised By: PROGRAMME OVERVIEW BIOLOGICS MAKE UP MORE THAN 1,000 MEDICINES AND VACCINES THAT TARGET MORE THAN 100 DISEASES. Unlike medicines
More informationThe Yale Center for Molecular Discovery. A Core Research Facility at Yale s West Campus
The Yale Center for Molecular Discovery A Core Research Facility at Yale s West Campus This is one-stop shopping for scientists who are looking to take the next step in advancing their research. Scott
More informationataluren overview A New Approach to Genetic Disorders
ataluren overview A New Approach to Genetic Disorders Ataluren Scientific Background What is ataluren? Ataluren(formerly PTC124) is the first investigational therapy with the potential to enable the formation
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationTuberculosis Drug Accelerator
Tuberculosis Drug Accelerator Overview of Activities and Portfolio who, why, what, how, by when and where are we now Steve Berthel 1 What is the Tuberculosis Drug Accelerator? The A is a groundbreaking
More informationThe long walk to a malaria-free world
1 The long walk to a malaria-free world Message from the Chairman and CEO Mr Ray Chambers Chairman of the Board Dr David Reddy MMV s CEO It always seems S impossible until it s done. Nelson Mandela (1918
More informationThe Aptuit Center for Drug Discovery & Development Verona, Italy
The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable
More informationJoint Technology Initiative: Innovative Medicine Initiative
Joint Technology Initiative: Innovative Medicine Initiative Dr John E Butler-Ransohoff Global External Innovation and Alliances Bayer HealthCare AG, Berlin/Wuppertal Bari, 30 April 2015 Largest Public
More informationManaging Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD
Managing Risk and Uncertainty Through the Drug Life cycle Recent FDA Initiatives Theresa Mullin, PhD Director Office of Strategic Programs US FDA Center for Drug Evaluation and Research October 14, 2014
More informationATIP Avenir Program 2018 Young group leader
ATIP Avenir Program 2018 Young group leader Important dates - October 17th (4 pm) 2017 : opening of the registrations online - November 23 th 2017: deadline for the online submission, the mailing of the
More informationNew WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research
New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research Hanne Bak Pedersen Programme Manager Health Technologies and Pharmaceuticals
More informationBSc Biomedical Science Degree
BSc Biomedical Science Degree Overview...2 BSc Biomedical Science...3 BSc Biomedical Science Pathway...4 BSc Biomedical Science Biochemistry Pathway...5 BSc Biomedical Science Pathway...6 BSc Biomedical
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More information105 AUSGABE 07 MAI 2014
105 AUSGABE 07 MAI 2014 DER NEUE FORSCHUNGSDRANG Dieser Mann hat Multiple Sklerose und sucht selbst nach einem Heilmittel. Wie der US-Amerikaner Scott Johnson zusammen mit der Hertie-Stiftung die Medikamentenforschung
More informationSingapore offers attractive
Singapore Biotech Guide 2008/2009 Singapore s Biomedical Sciences Landscape companies with spin offs to Singapore, while BMRC takes the lead in coordinating and funding public sector and academic research,
More informationAcademic Perspective: Institute for Systems Biology
Technological Aspects of Systems Biology The systems biology cycle can be stated as: perturbation-measurementmodel-hypothesis-perturbation, and so forth. In his article that reviews Hood s six points,
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationDes cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
More informationOpportunities in the Health Care Practice at Analysis Group
Opportunities in the Health Care Practice at Analysis Group Johns Hopkins Blomberg School of Public Health October 3, 2016 You Will Learn Today: Who the Analysis Group is What our Health Care Practice
More informationRegulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy?
Regulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy? EPLS September 24, 2014 Ulrich Granzer Granzer Regulatory Consulting & Services The Challenge: What needs to be done
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationIdorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
More informationPascal Quiry March 2013
Please send any questions on this case study to the author via the mail box on the web site www.vernimmen.com Pascal Quiry March 2013 This document may not be used, reproduced or sold without the authorisation
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationFrom Stem Cell to Any Cell
sciencenewsforkids.org http://www.sciencenewsforkids.org/2005/10/from-stem-cell-to-any-cell-2/ From Stem Cell to Any Cell By Emily Sohn / October 11, 2005 For maybe a day, about 9 months before you were
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationInsight to Gene Techno Science Co.,Ltd
Unlimited drug discovery from the beginning Ticker symbol: 4584 Insight to Gene Techno Science Co.,Ltd November 2017 2 Corporate Overview Chief Executive Founded March 2001 Masaharu Tani, President Listed
More informationPre-lab Homework Lab 1: Issues in Genetics
Lab Section: Name: Pre-lab Homework Lab 1: Issues in Genetics 1. Briefly define/explain the following terms in your own words. You may use any resource you can find, textbook, website, instructor, etc.,
More informationTo Our Shareholders: Reaching Patients with PNH and ahus
To Our Shareholders: In 2014, Alexion continued to expand its commercial and clinical operations as we advanced our mission to develop and deliver life-transforming therapies for patients with severe and
More informationResearch and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
More informationAn analysis of the Swedish Biotech Pipeline April, The Swedish Biotechnology Industry Organization
An analysis of the Swedish Biotech Pipeline April, 2007 The Swedish Biotechnology Industry Organization 0 A Survey of the Swedish Biotech pipeline In February-March 2007 a survey of the Swedish biotech
More information